/MOB.ST
MOB.ST Stock - Moberg Pharma AB (publ)
Healthcare|Drug Manufacturers - Specialty & GenericSTO
$10.04+4.58%
+$0.44 (+4.58%) • Dec 23
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $11.04
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MOB.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.94 – $10.14
TARGET (TP)$11.55
STOP LOSS$9.24
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.08
52W High$12.10
52W Low$6.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.81M | N/A | $207,000 | N/A | $33.66M |
| Gross Profit | $6.32M | $-2,099,000 | $-2,375,000 | $-2,584,000 | $33.66M |
| Gross Margin | 64.4% | N/A | -1147.3% | N/A | 100.0% |
| Operating Income | $-324,830,000 | $-27,463,000 | $-20,517,000 | $-19,730,000 | $-21,684,000 |
| Net Income | $-255,111,000 | $-21,093,000 | $-15,710,000 | $-16,222,000 | $-19,027,000 |
| Net Margin | -2600.3% | N/A | -7589.4% | N/A | -56.5% |
| EPS | $-6.74 | $-1.33 | $-1.38 | $-2.43 | $-6.51 |
Company Overview
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MOB.STBeat Rate
67%
Last 6 quarters
Avg Surprise
+178.9%
EPS vs Estimate
Beats / Misses
4/2
Last 12 quarters
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
+70.0%
$-0.03vs$-0.10
Q1 25
+1108.3%
$1.21vs$-0.12
Q2 25
No data
Q3 25
-53.8%
$-0.15vs$-0.10
Q4 25
+10.7%
$-0.09vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | $-0.10 | $-0.09 | +10.7% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.10 | $-0.15 | -53.8% | ✗ MISS |
Q2 2025 | May 13, 2025 | — | $-0.06 | — | — |
Q1 2025 | Feb 11, 2025 | $-0.12 | $1.21 | +1108.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.10 | $-0.03 | +70.0% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | — | $-0.13 | — | — |
Q2 2024 | May 7, 2024 | — | $-0.14 | — | — |
Q1 2024 | Feb 13, 2024 | — | $-0.23 | — | — |
Q4 2023 | Nov 7, 2023 | — | $-0.36 | — | — |
Q3 2023 | Aug 3, 2023 | — | $-0.26 | — | — |
Q2 2023 | May 9, 2023 | — | $-0.34 | — | — |
Q1 2023 | Feb 7, 2023 | — | $-0.21 | — | — |
Q4 2022 | Nov 8, 2022 | — | $-0.04 | — | — |
Q3 2022 | Aug 9, 2022 | — | $-0.06 | — | — |
Q2 2022 | May 10, 2022 | — | $-0.09 | — | — |
Q1 2022 | Feb 8, 2022 | $1.00 | $-0.10 | -110.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-1.68 | $-0.87 | +48.3% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | — | $-0.74 | — | — |
Latest News
Loading news...
Frequently Asked Questions about MOB.ST
What is MOB.ST's current stock price?
Moberg Pharma AB (publ) (MOB.ST) is currently trading at $10.04 per share. The stock has moved +4.58% today.
What is the analyst price target for MOB.ST?
No analyst price targets are currently available for this stock.
What sector is Moberg Pharma AB (publ) in?
Moberg Pharma AB (publ) operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the STO exchange.
What is MOB.ST's market cap?
Moberg Pharma AB (publ) has a market capitalization of $0.47 billion, making it a small-cap company.
Does MOB.ST pay dividends?
No, Moberg Pharma AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACARIX.ST
Acarix AB (publ)
$0.28
Mkt Cap: $0.3B
ACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
ALZCUR.ST
AlzeCure Pharma AB (publ)
$2.08
Mkt Cap: $0.2B
ENZY.ST
Enzymatica AB (publ)
$1.91
Mkt Cap: $0.5B
ERMA.ST
Enorama Pharma AB (publ)
$2.30
Mkt Cap: $0.2B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
IVACC.ST
Intervacc AB (publ)
$0.92
Mkt Cap: $0.3B
KLAR.ST
Klaria Pharma Holding AB (publ.)
$0.61
Mkt Cap: $0.2B
MAGLE.ST
Magle Chemoswed Holding AB (publ)
$17.20
Mkt Cap: $0.4B
NANEXA.ST
Nanexa AB (publ)
$4.21
Mkt Cap: $0.7B
Explore stocks similar to MOB.ST for comparison